Atara Biotherapeutics expands review of strategic alternatives for CAR-T assets

Atara had previously engaged a financial advisor to support the assessment of opportunities to advance and realize value from Atara’s CAR-T assets. The advisor’s scope has recently expanded to include a wider range of additional strategic alternatives which may include, but are not limited to, an acquisition, merger, reverse merger, other business combinations, sale of assets, or other strategic transactions. Through this process, Atara is already in active discussions with several potential parties. However, there can be no assurance regarding the results or outcome of this process. It is possible that Atara may not pursue a strategic alternative or transaction or that any strategic alternative or transaction, if pursued, will be completed on attractive terms, or that a strategic alternative or transaction may not ultimately be consummated.